VDX-111针对狗癌细胞系中的增殖途径
Kristen B Farrell1, Sunetra Das1, Steven K Nordeen2
1Department of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, United States of America.
PloS one
|May 21, 2024
概括
维生素D衍生物VDX-111在狗癌细胞中表现出抗癌活性. 它的有效性各不相同,与细胞信号通路如MAPK和PI3K-AKT相关,表明作为向治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 兽医医学 兽医医学 兽医医学
背景情况:
- 维生素D衍生物正在研究抗癌性质.
- VDX-111 (AMPI-109) 是一种新的维生素D衍生物,具有已证明的抗癌活性.
- 狗癌症研究为比较瘤学提供了有价值的模型.
研究的目的:
- 评估VDX-111对各种犬类癌症细胞系的有效性.
- 为了确定VDX-111敏感性的潜在预测标记.
- 为了研究VDX-111抗癌作用背后的分子机制.
主要方法:
- 在30个特征性犬癌细胞系上测试VDX-111.
- 评估生长抑制,细胞死亡和迁移抑制.
- 关联药物敏感性与细胞信号通路中的基因表达 (MAPK,PI3K-AKT).
主要成果:
- VDX-111在不同类型的狗癌症中显示出可变的疗效.
- 对VDX-111的敏感性与MAPK和PI3K-AKT通路中的基因表达有显著的相关性.
- 证实了这些信号通路的抑制是可能的作用机制.
结论:
- 一部分犬类瘤可能对VDX-111治疗敏感.
- 在MAPK和PI3K-AKT通路中的基因表达可以作为VDX-111敏感性的预测生物标志物.
- VDX-111对未来犬类瘤学临床试验具有前景.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


